The 2024 agenda will be available closer to the time of the meeting.
2023 agenda:
Friday, 17th March, 2023
Welcome Reception 6:30pm
Saturday 18th March, 2023; DAY 1
Introduction: Gareth Morgan & Keith Stewart 9:00am-9:10am
Overview lecture I; Gareth Morgan 9:10am-9:30am
Biology of HR
Session I: Genomics 2022 9:30am -10.50am
Chairs: Francesco Maura and Leif Bergsagel
- The genomics of and definition of SMM; Leif Bergsagel
- Utility of mutational and copy number signatures as prognostic factors; Kylee MacLachlan
- Time of origin and evolutionary trajectories to MM; Francesco Maura
- Molecular definitions of High-risk MM and their utility for trial entry; Jill Corre
- Clonal substructure and drivers of MM relapse; Niels Weinhold
Panel Discussion: What’s next in Genomics 10:20 am-10:50am
Coffee Break 10:50am-11:10am
Session II: Overview lecture II; Irene Ghobrial 11:10am-11:30am
Resistance mechanisms mediated via the Microenvironment
Chairs: Irene Ghobrial and Niels Weinhold 11:30am – 12:50pm
- Therapy resistance and utility of targeting apoptosis in MM; Lawrence Boise
- Microenvironment-mediated resistance to treatment; Madhav Dhodapkar
- Revlimid resistance as a clinical and biological entity; Charlotte Pawlyn
- Sequencing and IMiD resistance; Sarah Gooding
- Resistance and side effects of TCE-bispecifics; Samir Parekh
- Immune dependent mechanisms leading to resistance to T cell Engagers in Myeloma; Paola Neri
Panel Discussion: Overcoming Drug resistance 12:30pm-12:50pm
LUNCH 12:50pm -1:50pm
Session III: Novel targets 1.
Overview lecture III; Jesus San-Miguel 1:50pm-2:15pm
How to incorporate MRD in clinical trials and routine practice
Chairs: Charlotte Pawlyn and María-Victoria Mateos 2:15pm – 3:35pm
- Using the Vk*MYC mouse model to understand early stages of myelomagenesis; Marta Chesi
- Pre-clinical MM models for predicting clinical immunotherapy outcomes; José Ángel Martínez Climent
- Utility of Epigenetic analysis of MM plasma cells; Felipe Prosper
- Novel risk scores and endpoints for trials in SMM trials; Maria-Victoria Mateos
- • The biology of remission and of a high-risk microenvironment; Bruno Paiva
Panel Discussion: Future strategies for myeloma management 3:05pm-3:35pm
Break: 3:35pm -3:50pm
Overview lecture IV; Keith Stewart 3:50pm – 4:10pm
The future of MM therapy
Session IV: The future of myeloma therapy: 4:10pm-5:15pm
Chairs: Rafael Fonseca and George Mulligan
- The clinical utility of frailty in clinical trial designs; Claudia Stege
- Translational studies associated with current and planned trials of MM in the USA; Brian Walker
- Translational studies associated with current and planned trials of MM in Europe; Martin Kortüm
- Recent developments from trials of isatuximab; Fredrik Schjesvold
Group Discussion: Response and MRD directed therapy and in the clinic 4:50pm – 5:15pm
Wrap up and end Day1 5:15pm-5:20pm
Day 2 Sunday 19th March, 2023
Session V: Novel Targets 2: 09:00am-10:20am
Chairs: Elena Zamagni and Paola Neri
- Utilising imaging modalities as endpoints in clinical trials; Elena Zamagni
- The role of Iberdomide and Mezigomide in 2023 and beyond; Nizar Bahlis
- Other therapeutic vulnerabilities (Modakafusp, PDCs, BCL2 inhibitors…); Enrique Ocio
- Innovative CAR-T designs and targets; Carlos Fernández de Larrea
Panel Discussion: Developing novel targets for the clinic. 09:50am-10:10am
Coffee Break 10:10am-10:30am
Session VI: Debate curing MM and how to achieve it 10:30am-11:25am
Chairs: Gareth Morgan
- European Perspective; Pieter Sonneveld
- US Perspective; Sagar Lonial
Panel Discussion 10:55am-11:25am
Overview Lecture V; Maria-Victoria Mateos 11:25am-11:45am
T-cell engaging therapy
Session VII: T-Cell Engagers: 11:45am-1:15pm
Chairs: Maria-Victoria Mateos and Eric Smith
Update session on bispecifics and CAR-T cell therapy
- Teclistamab; Suzanne Trudel
- Elranatamab; Nizar Bahlis
- Ide-cel; Yi Lin
- Cilta-cel; Adam Cohen
- Talquetamab; Paula Rodriguez
- GPRC5D CAR T-cells; Eric Smith
Panel Discussion – Optimizing the use of Bi-specifics and CAR-T in the clinic 12:45pm-1:15pm
Summary and close of iwMyeloma 2023 1:15-1:30pm
Gareth Morgan, Keith Stewart
iwMyeloma Scientific Committee:
Keith Stewart (Co-Chair) USA, Gareth Morgan (Co-Chair) USA
Kenneth Anderson USA, Leif Bergsagel USA, Irene Ghobrial USA, Ola Langdren USA, Sagar Lonial USA, Maria-Victoria Mateos Spain, Jesus San-Miguel Spain, Pieter Sonneveld NL